(65 days)
Not Found
No
The summary describes a mechanical system for blood flow reversal and filtration, with no mention of AI, ML, image processing, or data-driven algorithms.
Yes
The device is intended to provide embolic protection during carotid artery angioplasty and stenting, which is a therapeutic intervention for carotid artery stenosis.
No
This device is described as an intervention system that reverses blood flow and removes embolic particles during a procedure, indicating a therapeutic rather than diagnostic function.
No
The device description clearly lists three primary hardware components: a balloon sheath, a balloon wire, and an external filter. The summary also describes performance studies involving biocompatibility, sterilization, shelf life, and functional/mechanical/physical evaluations, which are typical for hardware devices.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Description: The GORE® Flow Reversal System is a medical device used during a surgical procedure (carotid artery angioplasty and stenting) to physically manipulate blood flow and filter embolic particles. It does not analyze samples taken from the body.
- Intended Use: The intended use describes a therapeutic intervention during a procedure, not a diagnostic test performed on a sample.
Therefore, the GORE® Flow Reversal System is a therapeutic medical device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The GORE® Flow Reversal System is intended to provide embolic protection during carotid artery angioplasty and stenting for the patients diagnosed with carotid artery stenosis and who have the appropriate anatomy described below:
- Adequate iliac/femoral access .
- Common carotid artery diameters between 6 and 12 mm ●
- External carotid artery diameters less than 6 mm .
Product codes
NTE
Device Description
The GORE® Flow Reversal System consists of three primary components:
- GORE® Balloon Sheath .
- GORE® Balloon Wire .
- GORE® External Filter .
When assembled together, the GORE® Flow Reversal System reverses the flow of blood at the treatment site of the internal carotid artery (ICA), directing embolic particles away from the neurovascular circulation and removing them through an external filter.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
carotid artery, iliac/femoral access
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical evaluations of the modified GORE® Flow Reversal System included biocompatibility testing in accordance with ISO 10993-1, sterilization, shelf life, and performance testing, including functional, mechanical and physical evaluations. The results of these tests demonstrate that the technological characteristics such as product performance, design, materials and the intended use are substantially equivalent to the currently marketed predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.1250 Percutaneous catheter.
(a)
Identification. A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.(b)
Classification. Class II (performance standards).
0
K12 3156
W. L. Gore & Associates, Inc. Special 510(k) GORE® Flow Reversal System
510(k) SUMMARY [21 CFR 807.92(a)] 5
DEC 1 3 2012 1
-
- 510(k) Owner's Contact Information: name, address, phone and fax numbers, name of contact person, and date the summary was prepared [807.92(a){1)]
Applicant: W. L. Gore & Associates, Inc. 32360 N. North Valley Parkway Phoenix, AZ 85085
- 510(k) Owner's Contact Information: name, address, phone and fax numbers, name of contact person, and date the summary was prepared [807.92(a){1)]
Contact:
.
Sharon Alexander Requlatory Affairs Direct: (623) 234-5440 Fax: (623) 234-5105 Email: salexand@wlgore.com
Date Prepared:
October 3, 2012
-
- Name of the Device: including the trade or proprietary name, if applicable, the common or usual name, and the classification name, if known [807.92(a)(2)] 1
- GORE® Flow Reversal System . Trade name:
- Common name: .
Occlusion catheter
- Classification name: Temporary carotid catheter for embolic capture
- Classification: 21 CFR 870.1250, NTE, Class II C
-
- Device Predicate [807.92(a)(3)]
K083300, GORE® Flow Reversal System
- Description of the Device [807.92(a)(4)1
The GORE® Flow Reversal System consists of three primary components:
- GORE® Balloon Sheath .
- GORE® Balloon Wire .
- GORE® External Filter .
When assembled together, the GORE® Flow Reversal System reverses the flow of blood at the treatment site of the internal carotid artery (ICA), directing embolic particles away from the neurovascular circulation and removing them through an external filter.
-
- Intended Use [807.92(a)(4)]
The GORE® Flow Reversal System is intended to provide embolic protection during carotid artery angioplasty and stenting for the patients
- Intended Use [807.92(a)(4)]
GORE and Design are Trademarks of W. L. Gore & Associates, Inc.
1
W. L. Gore & Associates, Inc. Special 510(k) GORE® Flow Reversal System
5 510(k) SUMMARY [21 CFR 807.92(a)]
diagnosed with carotid artery stenosis and who have the appropriate anatomy described below:
- . Adequate iliac/femoral access
- Common carotid artery diameters between 6 and 12 mm .
- External carotid artery diameters less than 6 mm .
-
- Summary of Similarities and Difference in Technological Characteristics, Performance and Intended Use:
The modified GORE® Flow Reversal System is substantially equivalent to the currently marketed predicate device in its intended use, technological characteristics and performance.
-
- Predicate Device Comparison [807,92(a)(6)]
Non-clinical evaluations of the modified GORE® Flow Reversal System included biocompatibility testing in accordance with ISO 10993-1, sterilization, shelf life, and performance testing, including functional, mechanical and physical evaluations. The results of these tests demonstrate that the technological characteristics such as product performance, design, materials and the intended use are substantially equivalent to the currently marketed predicate device.
- Predicate Device Comparison [807,92(a)(6)]
8. Conclusion
The modified GORE® Flow Reversal System is substantially equivalent to the predicate GORE® Flow Reversal System (K083300) in terms of design, material composition, intended use and performance attributes.
2
Image /page/2/Picture/0 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal features the department's name in a circular arrangement around a stylized symbol. The symbol consists of three abstract human figures, representing the department's focus on health and human well-being. The text is in bold, sans-serif font.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center -- WO66-G609 Silver Spring, MD 20993-0002
DEC 1 3 2012
W.L. Gore & Associates, Inc. c/o Sharon Alexander, Regulatory Affairs Associate Medical Products Division 32360 N North Valley Parkway Phoenix, AZ 85085 United States
Re: K123156
Trade/Device: Gore Flow Reversal System Model Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: NTE Dated: October 3, 2012 Received: November 13, 2012
Dear Ms. Alexander:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
3
Page 2 - Ms. Sharon Alexander
device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours.
Bram Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
W. L. Gore & Associates, Inc. Special 510(k) GORE® Flow Reversal System
INDICATIONS FOR USE STATEMENT 4
Indications for Use
510(k) Number (if known):
Device Name:
GORE® Flow Reversal System
Indications for Use:
The GORE® Flow Reversal System is intended to provide embolic protection during carotid artery angioplasty and stenting for the patients diagnosed with carotid artery stenosis and who have the appropriate anatomy described below:
- Adequate iliac/femoral access .
- Common carotid artery diameters between 6 and 12 mm ●
- External carotid artery diameters less than 6 mm .
Prescription Use × (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER : PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sinn-Ori) 510 h; Number
GORE and Design are Trademarks of W. L. Gore & Associates, Inc. Confidential Information
16